News Archives - Page 2 of 2 - ELIAS Animal Health

ELIAS Animal Health announces clinical trial launch: ECI-OSA-04 for the treatment of canine osteosarcoma

Olathe, Kan., May 28, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a follow-up study to pursue licensure of the ELIAS cancer immunotherapy (ECI®) treatment combined with surgery as an alternative to chemotherapy for dogs diagnosed with osteosarcoma, a deadly form of bone cancer. In a preliminary clinical study, the median survival time was 415 days, compared to 270-300 days for traditional chemotherapy treatments, suggesting that ECI holds the potential to significantly improve survival times and quality of life for the canine patient. This clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. It will be a two-arm study with a 1:1 randomization comparing ECI and carboplatin, a type of chemotherapy. ELIAS is providing financial assistance that will substantially cover costs of participation and treatment [...]

By Jessica Wiley|2020-06-16T10:15:26-06:00May 28th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial|0 Comments

ELIAS Animal Health Clinical Dataset Supports FDA Fast Track Designation for TVAX Biomedical

Exciting progress in the fight against cancer for both pets and humans On April 27, the US Food and Drug Administration (FDA) approved the application by our development partner, TVAX Biomedical, for Fast Track Designation for treatment of glioblastoma multiforme (GBM) with the immunotherapy technology ELIAS Animal Health is also using for treatment of osteosarcoma in dogs. Founded on the principle of translational medicine, ELIAS is especially pleased to have supported this major achievement. The efficacy and safety data from the previously completed canine osteosarcoma study conducted by ELIAS was an important component of the TVAX Fast Track application and we are pleased that the results of that study contributed to the FDA’s approval of the GBM Fast Track application. This is a significant accomplishment in that Fast Track Designation is not easily granted by the FDA and requires TVAX to provide evidence of its ability to successfully treat a [...]

By Jessica Wiley|2023-01-06T15:41:25-06:00May 5th, 2020|Categories: News|Tags: cancer immunotherapy, canine osteosarcoma, clinical trial, translational medicine|0 Comments

ELIAS Animal Health announces appointment of Tammy Ham to Board of Directors

Olathe, Kan., March 18, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announces the appointment of Tammy Ham to its Board of Directors. Ms. Ham is President of BioNOVUS Innovations LLC, a Kansas City-based firm committed to investing in individuals and organizations who are transforming healthcare, and Chief Executive Officer of CicloMed LLC, a developmental-stage pharmaceutical company focusing on unmet needs in human oncology. “Tammy Ham is an established leader in the healthcare field and a fantastic addition to the ELIAS Board of Directors,” said Tammie Wahaus, CEO of ELIAS. “Her experience in leading the development of pharmaceutical products will prove invaluable as we work toward licensure of our canine cancer immunotherapy.” “I am excited to join the ELIAS Board of Directors and to be part of our region’s vibrant animal health community,” said Ms. Ham. “I am impressed with [...]

By Jessica Wiley|2022-01-20T13:10:05-06:00March 18th, 2020|Categories: News|Tags: elias leadership|0 Comments

ELIAS Animal Health announces new additions to leadership team ahead of clinical study launch

Olathe, Kan., February 26, 2020 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced today the appointment of Evan Courtemanche as Vice President of Manufacturing, and Jody Ehrhardt, as Director of Clinical Studies. Evan Courtemanche brings an extensive background in mammalian cell-culture manufacturing and supply chain functions in FDA and USDA-regulated therapeutics, and managing contract manufacturing relationships, both international and domestic. He currently oversees the biologics manufacturing processes and facility where the company’s USDA-regulated cancer immunotherapy is manufactured. Previously, Mr. Courtemanche served in manufacturing leadership and oversight roles for Aratana Therapeutics and Genzyme. Jody Ehrhardt, CCRC, brings more than 25 years of experience in clinical studies in both human and animal sciences. As the Director of Clinical Studies for ELIAS, she manages clinical study development, including protocol composition, study site recruitment and management, and regulatory reporting. Previously, she served as a [...]

By Jessica Wiley|2020-03-18T13:11:54-06:00February 26th, 2020|Categories: News|Tags: canine osteosarcoma, clinical trial|0 Comments

ELIAS Animal Health named a 2020 Kansas City Startup to Watch

ELIAS Animal Health has been named a 2020 Kansas City Startup to Watch by Startland News. The list of 10 startups is announced by Startland News each year and features innovative, entrepreneurial organizations making waves in the Kansas City area. “This nomination is a reflection of the hard work we’ve put in to bring our cancer immunotherapy to a broader audience,” said Tammie Wahaus, CEO of ELIAS. “I am excited to be included on this list of innovative companies in Kansas City, and look forward to a successful and impactful 2020.” Read the ELIAS Animal Health feature story, or view the full list startups on StartlandNews.com.

By Jessica Wiley|2020-01-22T16:59:26-06:00January 22nd, 2020|Categories: News|0 Comments

University announces advancement in canine cancer treatment

The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.

By Jessica Wiley|2020-02-26T15:08:42-06:00March 3rd, 2019|Categories: News|Tags: cancer immunotherapy, canine cancer, canine osteosarcoma, university of missouri|0 Comments